BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carisbamate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Carisbamate\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05219617-8747@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Carisbamate: Phase 3 readout est. (NCT05219617)
DESCRIPTION:Carisbamate\, phase 3\, Epilepsy.\nStudy: Investigate Efficacy 
 and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated 
 With LGS in Children and Adults\nEstimated primary completion: February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carisbamate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05219617
URL:https://assetmemo.bio/drug/carisbamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
